Browsing by Author "Altundag, O."
Now showing 1 - 4 of 4
- Results Per Page
- Sort Options
Item Adjuvant Radiotherapy in Clear Cell and Serous Papillary Endometrial Cancer(2015) Sari, S. Yuce; Gultekin, M.; Yuce, K.; Ayhan, A.; Altundag, O.; Kars, A.; Turker, A.; Ocalan, R.; Hurmuz, P.; Yildiz, F.; 0000-0003-0197-6622; W-9219-2019; ABX-1273-2022; AAJ-5802-2021Item EMPOWER-Lung 1: A Randomized, Open-Label, Multi-National, Phase III Trial of Cemiplimab, A Human PD-1 Monoclonal Antibody, Versus Chemotherapy In First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) With PD-L1 >= 50%(2018) Sriuranpong, V.; Altundag, O.; Clingan, P.; Rizvi, N.; Frontera, O. Aren; Sezer, A.; Paydas, S.; Shavdia, M.; Bondarenko, I.; Gladkov, O.; 0000-0003-0197-6622; 0000-0003-4642-3693; W-9219-2019; F-3132-2018Item Patterns of Recurrence and Survival Rates in Endometrial Cancer According to ESMO-ESGO-ESTRO Risk Classification(2018) Sari, S. Yuce; Gultekin, M.; Rahatli, S.; Altundag, O.; Turker, A.; Kars, A.; Yuce, K.; Ayhan, A.; Ozyigit, G.; Yildiz, F.; 0000-0003-3163-7429; 0000-0003-0197-6622; AAJ-3047-2021; W-9219-2019Item Surgical management and outcomes of metastatic tumors to the ovaries(2019) Rahatli, S.; Akilli, H.; Haberal, N.; Altundag, O.; Haberal, A.; Ayhan, A.Purpose of Investigation: Gynecologic and non-gynecologic tumors occasionally metastasize to the ovaries. Aim of this study was to describe the clinicopathologic characteristics and survival outcomes of patients with metastatic tumors to the ovaries. Materials and Methods: Between 2007-2017, 859 operations were performed in this center with initial diagnosis of ovarian mass. Seventy-five patients who had metastatic tumor to the ovaries in pathological examination were included the study. Results: Median overall survival of all patients was 26 +/- 5.9 months, three-year survival was 62%, and five-year survival was 37%. Patients who developed metachronous metastasis had better survival than patients who had synchronous metastasis (p = 0.05). Bilateral ovarian involvement was related with poor survival compared with unilateral involvement. Chemotherapy had beneficial effect on overall survival. Median survival in extensive surgery group was 30.9 months and it was better than minimal surgery group with 15.6 months, however it was not statistically significant (p= 0.973). Conclusion: The prognosis of the metastatic tumors to the ovaries is poor but achieving a complete resection and optimal debulking surgery may improve survival in some histologic subgroups.